Aptose Gets FDA Fast-Track Designation for HM43239

By Colin Kellaher

Aptose Biosciences Inc. on Wednesday said the U.S. Food and Drug Administration granted fast-track designation to HM43239 for the treatment of patients with relapsed or refractory acute myeloid leukemia with FLT3 mutation.

The Toronto clinical-stage oncology company is currently conducting a Phase 1/2 study of HM43239 in patients with the cancer of the blood and bone marrow.

The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs. The agency previously granted orphan-drug designation to HM43239 for treatment of acute myeloid leukemia in 2018.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

May 04, 2022 08:07 ET (12:07 GMT)

Aptose Biosciences (TSX:APS)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024